Taysha gene therapies announces expanded eligibility in reveal phase 1/2 adult trial to include adolescent rett syndrome patients

Health canada authorized the company's protocol amendment that expands eligibility to include patients aged 12 and older with stage four rett syndrome in the reveal phase 1/2 adult trial in canada
TSHA Ratings Summary
TSHA Quant Ranking